Loading clinical trials...

Pilot Trial of Supplemental Vitamin A and Nicotinamide | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide

NCT05702398•Rhode Island Hospital

Summary

The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years old or greater;
•Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or
•At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system);
•Understands, reads, and writes English proficiently.

Exclusion Criteria

•Liver disease;
•Active peptic ulcer disease;
•Recent myocardial infarction;
•Hypotension;
•Internal malignancy within past 5 years;
•Renal impairment with eGFR\<15 mL/min/1.73 m2;
•Being unable for follow up due to social reasons;
•Gorlin's syndrome or other genetic skin cancer syndrome;
•Huge number of current skin cancers;
•Metastatic SCC or invasive melanoma within the past 5 years;
+6 more criteria

Locations (1)

Rhode Island Hospital

Providence, Rhode Island, United States

Key Dates

Start Date

April 1, 2023

Primary Completion Date

January 1, 2028

Completion Date

March 1, 2028

Last Updated

March 20, 2026

Enrollment

ESTIMATED participants

Conditions

Skin CancerKidney Transplant Recipients

Interventions

Vitamin A

DRUG

Nicotinamide

DRUG

Other: Placebo

OTHER

Contacts

Eunyoung Cho, ScD

CONTACT

401-863-5895 Eunyoung_Cho@brown.edu

Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker

NCT07266142

Skin Cancer, Non-MelanomaSkin Cancer Melanoma

View study

RECRUITINGPHASE2

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

NCT04844528

Chronic Lymphocytic LeukemiaNon-melanoma Skin Cancer (NMSC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Inclusion Criteria

Exclusion Criteria

Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Tranexamic Acid in Nasal Mohs Reconstruction

Implementation of Teledermoscopy and Artificial Intelligence